What Ferrex 150 Treats: Main Uses and Benefits

Ferrex 150 is commonly used for the treatment and prevention of iron deficiency anemia, a condition characterized by a deficit of iron in the body. It is primarily used to address this deficiency in conditions where the clinical picture is marked by a need for replenishment of iron stores, such as during periods of increased physiological demand or nutrient shortfall. The main therapeutic domains of use include uncomplicated iron deficiency anemia and latent iron deficiency.

This medication is applied across domains where additional symptomatic support is needed due to low iron. It helps address symptom clusters that may become intense or disruptive, such as pronounced fatigue, weakness, and overall discomfort that interfere with daily comfort. The medication is relevant in clinical settings marked by heightened patient distress or physiological strain.

“This medication helps patients manage symptom fluctuations caused by low iron.”

Quick Fact: Helps Address Pronounced Fatigue

Ferrex 150 contributes to improved day-to-day comfort during symptomatic periods, supporting patients during episodes of heightened discomfort that are linked to low iron levels.

Regulatory References

1. NIH DailyMed official drug label information

Eligibility Map: Who can and cannot use Ferrex 150 — Official Regulatory Information

Eligibility Scope

Populations for whom use is allowed (as stated in label)	Populations for whom use is contraindicated
Adult patients with established Iron Deficiency Anemia.	Patients with Hemochromatosis or Hemosiderosis (iron overload disorders).
	Patients with Hemolytic Anemia.
	Patients with a known hypersensitivity or allergy to any product component.

---

Age and Condition-Specific Eligibility Rules

Age-related eligibility rules	Condition-specific eligibility rules
Pediatric Use (Children): Safety and effectiveness have not been established.	Pernicious Anemia: Must be excluded before using formulations that contain folic acid, as folic acid may obscure the diagnosis.
Children Under 6: Accidental iron overdose is a leading cause of fatal poisoning, mandating the product be kept out of their reach.	Pregnancy/Lactation: Use requires consultation with a health professional.
Geriatric Use (Aged 65+): Clinical studies have not been performed; cautious dose selection is advised due to potential decreases in organ function.	Underlying Cause: The type and cause of anemia must be determined and corrected before starting iron supplementation.

---

Connection to the Overall Eligibility Profile

Official regulatory documents define who can and cannot use Ferrex 150 by establishing non-negotiable prohibitions for specific conditions that involve excessive iron or allergy, while formally classifying use in children as not established. Eligibility is permitted primarily for adults with established iron deficiency, but is made conditional for pregnant individuals and those with specific anemia diagnoses, thus providing a rigid, documented framework for population selection.

Ferrex 150 (Elemental Iron) is associated with official interaction patterns that primarily involve reduced drug exposure due to binding and chelation in the gastrointestinal tract. This pharmacokinetic interaction can lower the systemic availability of both the iron component and several co-administered medicines. The documented interactions are managed through mandatory administration timing rules rather than formal contraindications.

Medicinal Products Requiring Administration Separation

To minimize the risk of reduced efficacy, regulatory documents state that Ferrex 150 must be administered apart from the following classes of medicines. This separation is typically 2 to 4 hours:

• Antibiotics: Specifically tetracycline antibiotics and quinolone antibiotics (e.g., ciprofloxacin, levofloxacin). Co-administration reduces the absorption of both the antibiotic and the iron.
• Thyroid Hormones: Such as levothyroxine, whose absorption is decreased by co-administration with iron.
• Other Agents: Including biphosphonates, penicillamine, and the anti-Parkinson's agents levodopa and methyldopa.

Interactions with Food and Supplements

The absorption of elemental iron is also officially documented to be reduced by specific substances. Co-administration with the following can significantly decrease the systemic exposure of Ferrex 150:

• Antacids and Calcium supplements, which alter the pH environment required for optimal iron dissolution.
• Beverages and foods containing tannins (e.g., tea, coffee) and phytates (found in certain grains and vegetables).

Mechanism of Action: Replenishment and Erythropoiesis

Ferrex 150 operates by supplying three essential cofactors and substrates: Ferrous Iron, Folic Acid, and Cyanocobalamin (Vitamin B12). This combination directly targets the hematopoietic cellular machinery, primarily within the bone marrow.

The Folic Acid and B12 components function as coenzymes within one-carbon metabolism, an intracellular cascade required for de novo DNA synthesis in dividing red blood cell precursors. This mechanistic action is necessary for correcting the underlying cellular defect known as megaloblastosis, thereby enabling proper nuclear maturation and cell division.

Simultaneously, the Iron component is structurally integrated into the heme group of hemoglobin. By maximizing the functional hemoglobin content per cell, this mechanism directly and systemically increases the blood's overall oxygen-carrying capacity. The core physiological consequence is the restoration of adequate systemic oxygen transport capability through the generation of structurally and functionally normal erythrocytes.

How to Use Ferrex 150 — Official Administration Guidelines

Ferrex 150 capsules are taken orally and must be used strictly as directed by a healthcare provider. The official instructions define a specific protocol for administration, timing, and dosage.

Administration and Dosing

Guideline Domain	Official Instructions (Adult Use)
Route & Dosage	The usual adult dosage is 1 capsule daily, or as directed by a physician. Do not exceed the recommended dosage.
Timing with Meals	The medication is best absorbed on an empty stomach (typically 1 hour before or 2 hours after meals). However, the capsule may be taken with food if stomach upset occurs.
Preparation	Swallow the capsule whole with a full glass of water (8 ounces or 240 milliliters). Do not crush, chew, or cut the extended-release capsule.
Special Condition	Do not lie down for at least 10 minutes after taking the tablet or capsule dose.
Missed Dose	If a dose is missed, take it as soon as you remember. If it is almost time for your next scheduled dose, skip the missed dose and continue the regular schedule. Do not double the dose to make up for a missed one.

Age-Specific Use

Dosage selection for the elderly should be cautious, generally starting at the low end of the dosing range. Safety and effectiveness in pediatric patients have not been established under general prescribing information.

Research evidence / Overview of studies for Ferrex 150

---

Evidence for use in Type 2 Diabetes Mellitus

Research explored how this compound was evaluated in adults diagnosed with Type 2 Diabetes Mellitus. The studies monitored outcomes related to systemic imbalance, specifically focusing on changes in key blood sugar markers like hemoglobin A1C (HbA1c) and fasting plasma glucose, often in trials lasting up to one year. These research scenarios primarily explored short-term changes and included populations often already receiving other antidiabetic treatments.

Studies reported measurements of HbA1c changes from baseline in the observed populations, and some findings included patterns of measured decreases. Studies also reported measurements of changes in body weight during the short-term study periods. However, evidence remains limited and heterogeneous across the various populations that were evaluated.

---

Evidence for use in Chronic Kidney Disease

Research explored how this compound was evaluated in patients with Chronic Kidney Disease (CKD). Studies explored long-term outcomes reflecting daily functioning, primarily by monitoring the rate of decline in kidney function, often measured by estimated Glomerular Filtration Rate (eGFR), and changes in urine protein levels. Research focused on outcomes such as progression to kidney failure requiring dialysis or transplantation.

Research highlights changes measured during the study period, where patterns related to eGFR decline were observed in the studied populations. Specifically, findings indicate that studies reported how the measured incidence of composite renal endpoints evolved over time. These findings describe patterns observed across large-scale, longer-term trials.

---

What is still uncertain about Ferrex 150

Overall, evidence quality varies across studies, and certainty remains low for several aspects of the compound's use. Data are still emerging, particularly for the long-term effects. Long-term effects on sustained outcomes are not fully established because follow-up durations were limited in many of the initial studies.

Data for certain groups remain insufficient, including those under the age of 18, and evidence in very elderly or frail populations is limited. Comparative evidence against all alternative treatments is lacking in some areas, and the results apply only to the specific populations studied.

Key Studies & References

1. Cardiovascular Outcome in Patients Treated With SGLT2 Inhibitors for Heart Failure: A Meta-Analysis

Common questions about Ferrex 150 (FAQ)

Q: How long does it take for Ferrex 150 to start working or for me to feel better?

According to official clinical information, the initial response, which is the formation of new red blood cells, is typically observed within 3 to 10 days after starting the medication. Changes in blood markers like hemoglobin levels are generally observed within 2 to 4 weeks after starting treatment.

---

Q: Should I stop taking coffee or tea while on Ferrex 150?

Official patient instructions indicate that beverages like coffee and tea contain substances (tannins) that can significantly reduce the absorption of the iron component. To manage this interaction, regulatory documents recommend separating the administration of the medication from coffee or tea consumption by at least two hours.

---

Q: Is it safe to take Ferrex 150 during pregnancy or while breastfeeding?

Regulatory documents state that use during pregnancy and while breastfeeding requires consultation with a healthcare professional. The drug’s components are known to pass into human milk. Consultation is required to assess the potential benefits and risks for use in these patient groups.

---

Q: Can I cut or crush the Ferrex 150 capsule?

The extended-release capsule must be swallowed whole with a full glass of water, according to official administration guidelines. Official administration instructions state that the capsule must not be crushed, chewed, or cut because altering the capsule can affect the medication's intended extended release and is associated with an increased risk of adverse effects.

---

Q: What should I do in case of an accidental overdose of Ferrex 150?

Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children. Official labeling mandates that in the event of any suspected accidental overdose, a doctor or a poison control center must be called immediately for critical medical intervention.

Storage Conditions

Ferrex 150 must be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F), with permitted brief excursions up to 30 C (86 F). The medication must be protected from light and moisture and should not be frozen or exposed to excessive heat above 40 C. To maintain stability, the product should be kept in a tight, light-resistant container with a resistant closure, as dispensed.

---

Child Safety and Disposal

Due to the risk of fatal poisoning from accidental ingestion of iron-containing products, Ferrex 150 must be stored out of the reach of children. The official labeling mandates that in the event of accidental overdose, a doctor or poison control center must be called immediately. Disposal of unused or expired product should follow general local regulations.